The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision, and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. EMA protects and promotes public and animal health by ensuring medicines are safe, effective, and of high quality. It works closely with national competent authorities of EU Member States and the European Commission, fostering a network that supports timely patient access to new medicines and monitors their ongoing safety.
Serves as the central operational hub for EMA's scientific committees, expert working parties, administrative staff, and the coordination of the European medicines regulatory network. It hosts meetings, manages regulatory submissions, and facilitates communication across the EU.
A modern, purpose-built office building designed with a focus on sustainability, collaboration, and transparency. It includes state-of-the-art meeting and conference facilities to accommodate international delegations and extensive scientific discussions.
A dynamic, multicultural, and highly scientific environment. The culture emphasizes collaboration with a vast network of experts, regulatory excellence, scientific integrity, and a strong commitment to public and animal health within the EU.
The Amsterdam headquarters symbolizes EMA's continued critical role in the European health system. Its strategic location in a major European hub enhances accessibility for stakeholders and strengthens its collaboration with EU member states and international partners following its relocation from London.
While EMA's regulatory remit is primarily the European Union and European Economic Area, its influence and collaborations are global. The agency works closely with international partners such as the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and other regulatory authorities worldwide. This cooperation aims to align scientific standards, share critical information on medicine safety and efficacy, participate in international initiatives like ICH (International Council for Harmonisation), and address global public health challenges, ensuring that European citizens benefit from global advancements in medicine.
Domenico Scarlattilaan 6
Amsterdam
North Holland
Netherlands
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, EMA' leadership includes:
EMA has been backed by several prominent investors over the years, including:
The European Medicines Agency has seen some key appointments at the Head of Department level in the last 12 months, strengthening its governance and operational capabilities. The core senior leadership team, including the Executive Director, has remained stable.
Discover the tools EMA uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
The European Medicines Agency (EMA) primarily uses the firstname.lastname@ema.europa.eu email format for its staff. This is a common structure for official communications within the agency.
firstname.lastname@ema.europa.eu
Format
emer.cooke@ema.europa.eu
Example
90%
Success rate
European Medicines Agency Website • May 28, 2024
The CHMP recommended eight medicines for approval, including new treatments for generalized myasthenia gravis, Duchenne muscular dystrophy, and type 2 diabetes. They also recommended extensions of indication for six medicines already authorised in the EU....more
Reuters • May 17, 2024
The European Medicines Agency's human medicines committee (CHMP) recommended the authorization of an updated version of Moderna's COVID-19 vaccine, Spikevax, targeting the JN.1 coronavirus subvariant....more
European Medicines Agency Website • April 26, 2024
EMA’s human medicines committee (CHMP) has recommended granting marketing authorisations in the European Union (EU) for two vaccines to protect adults from disease caused by the chikungunya virus (CHIKV)....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including EMA, are just a search away.